NK/T Cell Lymphoma Clinical Trials

25 clinical trials for NK/T Cell Lymphoma across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma — RECRUITING · PHASE1
• Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma — RECRUITING · PHASE1
• A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma — RECRUITING · PHASE2
• RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies — RECRUITING · PHASE1
• PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma — RECRUITING · NA
• Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma — RECRUITING · PHASE2
• TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma — NOT_YET_RECRUITING · PHASE3
• Circulating Tumor DNA in Peripheral T-cell Lymphomas — ACTIVE_NOT_RECRUITING
• Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL — NOT_YET_RECRUITING · PHASE2
• A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma — TERMINATED · PHASE1
• Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma — NOT_YET_RECRUITING · PHASE2
• Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma — NOT_YET_RECRUITING · PHASE2
• A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) — COMPLETED · PHASE2
• A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL — ACTIVE_NOT_RECRUITING · PHASE1
• Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types — COMPLETED · PHASE2
• An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma — OTHER · PHASE1
• Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas — COMPLETED · PHASE1
• Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma — OTHER · PHASE2
• Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma — WITHDRAWN · PHASE1
• CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia — OTHER · PHASE1
• A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma — OTHER · PHASE4
• Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies — OTHER · PHASE1
• PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma — OTHER · PHASE4
• PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma — OTHER · PHASE2
• Gemcitabine in NK/T Cell Lymphoma — COMPLETED

Refine this search